Historical Valuation
Arbutus Biopharma Corp (ABUS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 642.12 is considered Overvalued compared with the five-year average of -8.78. The fair price of Arbutus Biopharma Corp (ABUS) is between 0.60 to 3.05 according to relative valuation methord. Compared to the current price of 4.65 USD , Arbutus Biopharma Corp is Overvalued By 52.22%.
Relative Value
Fair Zone
0.60-3.05
Current Price：4.65
52.22%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Arbutus Biopharma Corp (ABUS) has a current Price-to-Book (P/B) ratio of 11.83. Compared to its 3-year average P/B ratio of 5.53 , the current P/B ratio is approximately 114.03% higher. Relative to its 5-year average P/B ratio of 2.07, the current P/B ratio is about 470.30% higher. Arbutus Biopharma Corp (ABUS) has a Forward Free Cash Flow (FCF) yield of approximately -4.94%. Compared to its 3-year average FCF yield of -13.99%, the current FCF yield is approximately -64.65% lower. Relative to its 5-year average FCF yield of -13.93% , the current FCF yield is about -64.50% lower.
P/B
Median3y
5.53
Median5y
2.07
FCF Yield
Median3y
-13.99
Median5y
-13.93
Competitors Valuation Multiple
AI Analysis for ABUS
The average P/S ratio for ABUS competitors is 68.62, providing a benchmark for relative valuation. Arbutus Biopharma Corp Corp (ABUS.O) exhibits a P/S ratio of 642.12, which is 835.74% above the industry average. Given its robust revenue growth of -60.49%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ABUS
1Y
3Y
5Y
Market capitalization of ABUS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ABUS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ABUS currently overvalued or undervalued?
Arbutus Biopharma Corp (ABUS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 642.12 is considered Overvalued compared with the five-year average of -8.78. The fair price of Arbutus Biopharma Corp (ABUS) is between 0.60 to 3.05 according to relative valuation methord. Compared to the current price of 4.65 USD , Arbutus Biopharma Corp is Overvalued By 52.22% .
What is Arbutus Biopharma Corp (ABUS) fair value?
ABUS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Arbutus Biopharma Corp (ABUS) is between 0.60 to 3.05 according to relative valuation methord.
How does ABUS's valuation metrics compare to the industry average?
The average P/S ratio for ABUS's competitors is 68.62, providing a benchmark for relative valuation. Arbutus Biopharma Corp Corp (ABUS) exhibits a P/S ratio of 642.12, which is 835.74% above the industry average. Given its robust revenue growth of -60.49%, this premium appears unsustainable.
What is the current P/B ratio for Arbutus Biopharma Corp (ABUS) as of Jan 09 2026?
As of Jan 09 2026, Arbutus Biopharma Corp (ABUS) has a P/B ratio of 11.83. This indicates that the market values ABUS at 11.83 times its book value.
What is the current FCF Yield for Arbutus Biopharma Corp (ABUS) as of Jan 09 2026?
As of Jan 09 2026, Arbutus Biopharma Corp (ABUS) has a FCF Yield of -4.94%. This means that for every dollar of Arbutus Biopharma Corp’s market capitalization, the company generates -4.94 cents in free cash flow.
What is the current Forward P/E ratio for Arbutus Biopharma Corp (ABUS) as of Jan 09 2026?
As of Jan 09 2026, Arbutus Biopharma Corp (ABUS) has a Forward P/E ratio of -30.19. This means the market is willing to pay $-30.19 for every dollar of Arbutus Biopharma Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Arbutus Biopharma Corp (ABUS) as of Jan 09 2026?
As of Jan 09 2026, Arbutus Biopharma Corp (ABUS) has a Forward P/S ratio of 642.12. This means the market is valuing ABUS at $642.12 for every dollar of expected revenue over the next 12 months.